Most patients with inflammatory bowel disease (IBD), comprising
|
|
- Eleanor Bryant
- 5 years ago
- Views:
Transcription
1 FUTURE DIRECTIONS AND METHODS IN IBD RESEARCH Quality of Care and Outcomes Among Hospitalized Inflammatory Bowel Disease Patients: A Multicenter Retrospective Study Geoffrey C. Nguyen, MD, PhD,*, Sanjay K. Murthy, MD, MSc,, Brian Bressler, MD, MSc, Mindy C. W. Lam, MD, Ali Alali, MD,* Asmae Toumi, BSc, k Jason Reinglas, MD, Adam Rampersad, BSc, k Adam V. Weizman, MD, MSc,* and Waqqas Afif, MD, MSc, k on behalf of the CINERGI group Background: Half of patients with inflammatory bowel disease (IBD) require hospitalization. We sought to characterize inpatient quality indicators of care and outcomes during IBD-related hospitalizations at 4 major IBD referral centers in Canada. Methods: We conducted a multicenter retrospective cohort study of patients with IBD admitted from 2011 to 2013 to tertiary centers in Toronto, Montreal, Ottawa, and Vancouver. We assessed the following inpatient indicators of care: pharmacological venous thromboembolism (VTE) prophylaxis, Clostridium difficile testing, and medical rescue therapy for steroid-refractory ulcerative colitis (UC). We also evaluated rates of VTE, C. difficile infection, and IBD-related surgery. Results: There were 837 patients hospitalized for IBD (Crohn s disease, 59%; UC, 41%). The proportion of patients with IBD who received VTE prophylaxis and C. difficile testing were 77% and 82%, respectively, although these indicators varied significantly by center and admitting specialty. Patients admitted under surgeons were more likely than those admitted under gastroenterologists to receive VTE prophylaxis (84% versus 74%, P ¼ 0.016) but less likely to be tested for C. difficile (41% versus 88%, P, ). The rate of VTE was the same for those who did and did not receive VTE prophylaxis (2.2 per 1000 hospital-days). Among the 14 VTE events, 79% had received prophylaxis, but only 36% within 24 hours of admission. Among steroid-refractory UC patients, 70% received rescue therapy within 7 days of steroid initiation. The proportion of patients with UC and CD who required respective bowel surgery was 18% and 20%, respectively. Conclusions: There are opportunities to optimize quality of care among hospitalized patients with IBD. (Inflamm Bowel Dis 2017;23: ) Key Words: venous thromboembolism, Crohn s disease, ulcerative colitis, Clostridium difficile, surgery Most patients with inflammatory bowel disease (IBD), comprising Crohn s disease (CD) and ulcerative colitis (UC), are managed in the outpatient setting. However, hospitalization is required in half of patients during their disease course. 1 Reports suggest that hospitalizations for IBD are rising in North America and occur more often early in the course of the disease. 2 Within the first 2 years of diagnosis, 24% of patients with CD and 20% of patients with UC require an inpatient stay. 3 During hospitalization, patients with IBD are at increased risk of venous thromboembolic events (VTE) and Clostridium Received for publication November 29, 2016; Accepted January 29, From the *Mount Sinai Hospital Centre for Inflammatory Bowel Disease, Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada; Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, The Ottawa Hospital IBD Centre, University of Ottawa, Ottawa, Ontario, Canada; Division of Gastroenterology, St. Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada; and k Division of Gastroenterology, McGill University, Montreal, Québec, Canada. S. K. Murthy: Abbvie, Takeda, Shire, Ferring (Advisor/Speaker). B. Bresslerv: Shire, Ferring, Janssen, Abbvie, Takeda, Actavis (Advisor/Speaker); Amgen, Pendopharm, Genentech, Celltrion, Pfizer, Allergan (Advisor); Janssen, Abbvie, GSK, BMS, Amgen, Genentech, Merck, RedHill Biopharm, BI, Qu Biologic, Celgene, Alvine (Research Support); Qu Biologic (Stock options). A. V. Weizman: Janssen, Abbvie, Shire, Takeda (Advisor/Speaker). W. Afif: Abbvie, Janssen, Takeda, Shire, Ferring, Merck, Pfizer (Advisor); Abbvie, Janssen, Prometheus, Theradiag (Research Support). G. C. Nguyen, B. Bresslerv, S. K. Murthy, A. V. Weizman, and W. Afif are practicing gastroenterologists at their respective institutions involved in this study. The remaining authors have no conflict of interest to disclose. The Canadian IBD NEtwork for Research and Growth in Quality Improvement (CINERGI) group includes the following: G. C. Nguyen (University of Toronto); J. L. Jones (Dalhousie University); W. Afif (McGill University); B. Bressler (University of British Columbia); S. Fowler (University of Saskatchewan); S. Halder (McMaster University); V. W. Huang (University of Alberta); R. Khanna (Western University); S. K. Murthy (University of Ottawa); Joannie Ruel (University of Sherbrooke); C. H. Seow (University of Calgary); L. E. Targownik (University of Manitoba); A. V. Weizman (University of Toronto). Address correspondence to: Geoffrey C. Nguyen, MD, PhD, 600 University Avenue, Suite 437, Toronto, ON M5G 1X5, Canada ( geoff.nguyen@utoronto.ca). Copyright 2017 Crohn s & Colitis Foundation DOI /MIB Published online 21 March Inflamm Bowel Dis Volume 23, Number 5, May
2 Nguyen et al Inflamm Bowel Dis Volume 23, Number 5, May 2017 difficile infection, which are associated with greater than 2-fold and nearly 4-fold increase in-hospital mortality, respectively. 4 6 Accordingly, clinical practice guidelines recommend pharmacological VTE prophylaxis and testing for C. difficile for patients hospitalized for IBD. 7,8 Moreover, the American Gastroenterological Association has included VTE prophylaxis and C. difficile testing as inpatient quality indicators in its IBD Performance Measure Set. 9 Furthermore, nearly two-thirds of patients who are hospitalized for severe UC are unresponsive to intravenous corticosteroids and require rescue therapy with infliximab, cyclosporine, or colectomy. 10 Current clinical guidelines recommend that rescue therapy be considered for inadequate steroid response after 3 days. 7 The administration of rescue therapy within 7 days of steroid initiation has been suggested as an additional inpatient quality indicator in Canada. 11 However, it is unclear whether a higher standard for rescue therapy within 4 days of steroid initiation should be considered. Previous studies from the United States suggest there may be substantial geographic variation in the inpatient management of IBD. 12 We conducted a multicenter study of IBD hospitalizations among tertiary IBD centers in Canada s 4 largest metropolitan areas (Toronto, Montreal, Vancouver, and Ottawa) to determine the frequency to which inpatient quality indicators are being adhered. Secondary aims were to assess for geographic variations in inpatient quality indicators across the 4 centers and to evaluate rates of adverse clinical outcomes. 13 METHODS Data Sources A retrospective chart review of IBD admissions was independently conducted at 4 high-volume referral centers in each of the following major Canadian cities: Toronto, Ontario (Mount Sinai Hospital); Montreal, Quebec (McGill University Health Centre), Ottawa, Ontario (The Ottawa Hospital); and Vancouver, British Columbia (St. Paul s Hospital). Data were extracted from electronic and paper charts, with access to clinical information, laboratory investigations, endoscopic evaluations, pharmacological records, and discharge summaries. Eligibility Criteria We identified admissions with a most responsible diagnosis for IBD using International Classification of Diseases, Ninth Revision and International Classification of Diseases, Tenth Revision codes for UC (556.x and K51, respectively) and CD (555.x and K50, respectively) from 2011 to The medical charts were reviewed to confirm diagnosis. Only patients with IBD who were admitted for treatment of active disease for more than 24 hours were included. We excluded patients with IBD who were admitted electively for diagnostic or surgical procedures or who were admitted for a non-ibd indication. Data Collection Predictor Variables Patient demographic information and clinical characteristics were collected and included: age at admission, sex, IBD diagnosis (CD, UC, or IBD unclassified), and presence of hemodynamically significant gastrointestinal bleeding on admission. We also recorded admission-related factors, including the primary admitting service (gastroenterology, internal medicine, surgery, or other); and weekend versus weekday admissions. When available, the medical chart, phenotype data using the Montreal classification were also abstracted and included disease extent for UC and disease location and behavior for CD. Outcomes Outcomes were assessed through review of the inpatient record including the discharge summary, physician and nursing notes, diagnostic testing and endoscopy reports, and medical administration record. We assessed the following inpatient quality of care indicators: occurrence and timing of VTE prophylaxis; C. difficile testing (performed by polymerase chain reaction at all sites); and medical rescue therapy for steroid-refractory UC administered within 7 days of steroid initiation. In determining whether or not VTE prophylaxis was administered, we excluded admissions in which patients presented with hemodynamically significant bleeding. Among those who did receive pharmacological prophylaxis, we collected additional data on whether it was administered within 24 hours of admission, type of VTE prophylaxis used, and duration of therapy. For evaluation of the rate of C. difficile testing, we included only admissions in which patients presented with diarrhea. We collected data on the following outcomes using standardized collection forms: VTE events, major bleeding events related to VTE prophylaxis, C. difficile infection detected by polymerase chain reaction assay, and bowel resection during hospital admission. We defined major bleeding as: intracranial, intraspinal, or retroperitoneal bleeding; bleeding into any major organ; or postoperative bleeding that lead to reoperation. We also ascertained whether major bleeding required transfusion of packed red blood cells. Statistical Analysis We performed statistical analysis using Stata 14 SE (StataCorp LP, College Station, TX). Descriptive analysis was conducted to compare demographic and clinical characteristics of patients among the 4 participating centers. The chi-square and Fisher s exact tests were used to compare categorical variables, whereas the Student s t test was used to compare continuous variables. Multivariate logistic regression was used to identify predictors of VTE prophylaxis and C. diff testing while simultaneously adjusting for each of the predictors. A robust variance estimator was used to account for clustering by site, service, and physician provider. The unadjusted proportion of patients who received VTE prophylaxis and those who received it within 24 hours were calculated and stratified by primary service. The crude rates of minor and major bleeding were calculated by dividing the 696
3 Inflamm Bowel Dis Volume 23, Number 5, May 2017 Inpatient IBD Quality of Care total number of events by the number of total person-days on prophylactic anticoagulation. For those who did not receive VTE prophylaxis, the rate was calculated using the total person-days in hospital as the denominator. Ethical Considerations The Research Ethics Board at Mount Sinai Hospital (Toronto, Ontario), McGill University Health Centre (Montreal, Quebec), the Ottawa Hospital (Ottawa, Ontario), and St. Paul s Hospital (Vancouver, British Columbia) approved the study protocol. RESULTS There were a total 837 patients hospitalized for IBD during the study period, of which 493 were for CD (59%), 343 were for UC (41%), and 1 (0.1%) was for IBD unclassified. The number of hospitalizations at each specific site was as follows: Toronto, 243 (29%); Montreal, 151 (18%); Ottawa, 271 (32%); and Vancouver, 172 (21%). The clinical and demographic characteristics of subjects at each hospital site are given in Table 1. Most IBD-related hospitalizations (62%) were under the gastroenterologist service though this varied by site. Pharmacological VTE Prophylaxis Pharmacological VTE prophylaxis was administered to 77% of hospitalized patients with IBD, although this varied by location: ranging from 62% in Montreal to 84% in Ottawa (Table 2). Overall, 62% received anticoagulation within 24 hours of admission but this indicator differed significantly by hospital site, ranging from 26% in Montreal to 76% in Ottawa (Table 2). There was also hospital-based variation in preference of pharmacological agents: whereas low molecular weight heparin was strongly favored in Toronto (97%), Montreal (73%), and Ottawa (87%), unfractionated heparin (46%) and low molecular weight heparin (54%) were preferred in Vancouver. Admissions under general surgery were more likely to receive VTE prophylaxis compared with the gastroenterology service (84% versus 74%, P ¼ 0.016; adjusted odds ratio, 2.07; 95% confidence interval, ). However, the VTE prophylaxis rate within 24 hours of admission did not significantly differ by the admitting service (Fig. 1). Interestingly, IBD admissions on the weekend were less likely to receive VTE prophylaxis within 24 hours of admission only if admitted under gastroenterology (51% versus 65%, P ¼ 0.017; adjusted odds ratio, 0.57; 95% confidence TABLE 1. Demographic and Clinical Characteristics of Hospitalized IBD Patients Stratified by Hospital Center Hospital Center Demographic Variables Overall (N ¼ 837) Toronto (N ¼ 243) Montreal (N ¼ 151) Ottawa (N ¼ 271) Vancouver (N ¼ 172) Global P Age (mean 6 SD) Sex Male 391 (47) 98 (41) 83 (55) 126 (47) 84 (49) Female 443 (53) 143 (59) 68 (45) 144 (53) 88 (51) Primary service,0.001 Gastroenterology 520 (62) 150 (62) 57 (38) 189 (70) 124 (72) General internal medicine 142 (17) 52 (22) 36 (24) 45 (17) 9 (5) General surgery 167 (20) 39 (16) 57 (38) 32 (12) 39 (23) Other #5 #5 #5 #5 #5 Weekend admission 150 (18) 39 (16) 21 (14) 65 (24) 25 (15) Bleeding on admission 406 (51) 134 (56) 48 (32) 161 (60) 63 (44),0.001 Hemodynamically significant 63 (8) #5 36 (24) 7 (3) 15 (10),0.001 IBD diagnosis 0.32 UC 343 (41) 104 (43) 53 (35) 113 (42) 73 (42) CD 493 (59) 139 (57) 97 (64) 158 (58) 99 (58) IBD unclassified #5 #5 #5 #5 #5 Comorbidity,0.001 None 768 (92) 232 (95) 151 (100) 233 (86) 152 (89) 1 comorbidity 51 (6) 6 (3) #5 28 (10) 17 (10) $2 comorbidities 17 (2) #5 #5 10 (4) #5 CD presentation,0.001 Inflammatory 183 (42) 81 (59) 15 (21) 77 (49) 10 (15) Stricturing 160 (37) 30 (22) 35 (49) 62 (40) 33 (49) Penetrating 92 (21) 27 (20) 22 (31) 18 (11) 25 (37) 697
4 Nguyen et al Inflamm Bowel Dis Volume 23, Number 5, May 2017 TABLE 2. Quality Indicators and Outcomes of Hospitalized Patients with IBD Stratified by Hospital Center Hospital Center Overall (N ¼ 837) Toronto (N ¼ 243) Montreal (N ¼ 151) Ottawa (N ¼ 271) Vancouver (N ¼ 172) Global P Quality indicators of care VTE prophylaxis 572 (77) 191 (81) 71 (62) 219 (84) 91 (70),0.001 Within 24 hours of admission 457 (62) 154 (65) 30 (26) 198 (76) 75 (58),0.001 C. difficile testing 451 (82) 173 (91) 53 (61) 166 (83) 59 (81),0.001 Rescue therapy within 7 days of steroid initiation (UC only) 53 (70) 20 (61) #5 (75) 30 (77) N/A 0.32 Rescue therapy within 4 days of steroid initiation (UC only) 11 (14) #5 (12) #5 (50) #5 (13) N/A 0.19 Outcomes In-hospital VTE (per 1000 hospital-days) 2.2/ /1000 a 3.8/ /1000 a 4.9/1000 N/A Major bleeding (per 1000 hospital-days) 6.0/1000 0/1000 a,b 1.9/1000 b 17.7/ /1000 N/A C. difficile positive test, n (%) 50 (11) 20 (12) #5 (8) 20 (12) 6 (10) 0.66 Steroid responsiveness, n (%) 135 (54) 55 (54) 24 (52) 56 (55) N/A 0.93 Bowel surgery (CD only, %) 99 (20) 19 (14) 30 (31) 14 (9) 36 (36),0.001 Colectomy (UC only, %) 60 (18) 17 (17) 21 (40) 7 (6) 15 (21),0.001 N/A, not available. a P, 0.05 compared with Vancouver. b P, 0.01 compared with Ottawa. interval, ) but not general medicine or surgery. The presence of gastrointestinal bleeding (not hemodynamically significant) on admission was associated with higher rates of VTE prophylaxis within 24 hours (67% versus 57%, P ¼ 0.005). Safety and Effectiveness of Pharmacological VTE Prophylaxis The rate of major bleeding was not significantly higher in the group who received VTE prophylaxis compared with those who did not (7.6 versus 6.0 per 1000 hospital-days, P ¼ 0.62). The rate FIGURE 1. Inpatient quality indicators of care by specialty of admitting service. The proportion of admissions that received VTE prophylaxis, VTE prophylaxis within 24 hours of admission, C. difficile testing, and initiation of medical rescue therapy (among steroid-refractory UC admissions) within 7 days of steroid start are shown stratified by admitting service (gastroenterology, general internal medicine, or general surgery). Statistically significant differences (P, 0.05) compared with gastroenterology specialty are indicated with an asterisk (*)
5 Inflamm Bowel Dis Volume 23, Number 5, May 2017 Inpatient IBD Quality of Care of major bleeding requiring blood transfusion also did not differ (3.2 versus 3.0 per 1000 hospital-days, P ¼ 0.96). Among those receiving VTE prophylaxis, the rate of major bleeding did vary by hospital site (Table 2), ranging from 0/1000 in Toronto to 17.7/ 1000 in Ottawa. The overall rate of VTE during hospitalization was 2.2 per 1000 hospital-days and was higher in Montreal (3.8/1000 hospitaldays) and Vancouver (4.9/1000 hospital-days) compared with Toronto (0.9/1000 hospital-days) and Ottawa (1.0/1000 hospital-days), where VTE prophylaxis rates were higher. The anatomical location of the 14 VTE events were 29% lower extremities, 21% pulmonary embolism, 36% upper extremities, and 14% other site. However, VTE rate did not significantly differ between those who did and did not receive VTE prophylaxis (2.2 versus 2.2 per 1000 hospital-days, P ¼ 0.95). The VTE rate was lower among those who received VTE prophylaxis within 24 hours of admission compared with those who never received any prophylaxis (1.2 versus 2.2/1000 hospital-days, P ¼ 0.4). Among those who had VTE events during hospitalization, 79% (n ¼ 11/14) had received VTE prophylaxis. Nearly three-quarter (73%) of patients (n ¼ 8/11) who developed VTE while on VTE prophylaxis did not have any surgical procedures during hospitalization. However, only 36% of those with VTE received VTE prophylaxis within 24 hours of admission. Testing for C. difficile Although the overall rate of C. difficile testing among patients with UC and CD with diarrhea was 82%, there was variation with geographic location, ranging from 61% in Montreal to 91% in Toronto (Fig. 1). Testing was similarly high among admissions to gastroenterology and general medicine (88% and 87%, respectively) but considerably lower in those admitted to general surgery (41%, P, ; adjusted odds ratio, 0.12; 95% confidence interval, ). The prevalence of C. difficile positivity among those tested was 11%, and this did not significantly vary with location (Table 2). Medical Therapy in UC Among hospitalized patients with UC treated with systemic steroids, 58% demonstrated adequate clinical response and therefore required neither change in therapy nor surgery. The overall steroid responsiveness rate was 54% and did not vary by site (Table 2); data were not available for Vancouver. Among those with inadequate response to medical therapy, 76 (79%) received medical rescue therapy, and this did not significantly vary by geographic site. Ninety-nine percent of those who required medical rescue therapy received infliximab. Among individuals receiving rescue therapy, 70% received it within 7 days of starting steroids. This proportion was lower in Toronto (61%) than in Montreal (75%) and Ottawa (77%), although this was not statistically significant (P ¼ 0.3). Only 14% of patients with UC received second-line therapy within 4 days of initiating systemic steroids. In Toronto and Ottawa, the proportions were 12% and 13%, respectively, whereas it was 50% in Montreal (P ¼ 0.19). There was no difference between patients admitted to gastroenterology and general internal medicine with respect to receiving rescue therapy within 7 days (70% versus 78%; P ¼ 0.4) or 4 days (13% versus 17%, P ¼ 0.5). Surgery Among hospitalized patients with UC, 18% underwent colectomy during hospitalization. There was substantial variation in the proportion requiring surgery by geographic location: Ottawa (6%), Toronto (17%), Vancouver (21%), and Montreal (40%). Among steroid-refractory UC patients, the colectomy rate was 25% with following site-specific rates: Ottawa (16%), Toronto (33%), and Montreal (40%); P ¼ Nineteen percent of patients with UC who did not respond to steroids underwent colectomy without attempting rescue therapy. Among the remaining patients who did receive rescue therapy, 92% were able to avoid surgery during hospitalization. The overall rate of bowel resection for hospitalized patients with CD was 20%. As in UC, there was substantial variation by geographic location: Ottawa (9%), Toronto (14%), Montreal (31%), and Vancouver (36%). DISCUSSION In this large multicenter retrospective study, we identified significant variations in inpatient quality indicators and outcomes across centers and admitting services. These findings may reflect opportunities to optimize quality of care. Because of the increased mortality associated with VTE and C. difficile infection, processes of care to prevent or promptly treat these complications are cardinal in improving hospital outcomes. Numerous studies have confirmed that patients with IBD are at increased risk of VTE. 14 The absolute risk of VTE is highest during hospitalization where it is associated with 2-fold higher risk of mortality. 4,15 Thus, clinical practice guidelines have recommended pharmacological VTE prophylaxis for all hospitalized patients with IBD with the exception of those with hemodynamically significant gastrointestinal bleeding. 8 Prophylaxis rates among tertiary centers in our study far exceed those reported in a Canadian population-based study (including community hospitals) where VTE prophylaxis was,20%. 16 Our finding of differences in VTE prophylaxis among specialty services suggests there may be physician-based factors. For example, there may be greater VTE awareness among surgical services that has been previously described. 17 Variations in VTE prophylaxis across centers may reflect suboptimal quality of care, and may present an opportunity to introduce system-wide interventions, such as standardized IBD order sets, that may improve VTE prophylaxis. The use of electronic alert system and a pharmacist advocate were reported to be associated with increased implementation of VTE prophylaxis. 18,19 Interestingly, we found no difference in rates of VTE between those who did and did not receive VTE prophylaxis. Moreover, 79% of the mostly nonsurgical patients with VTE had received VTE prophylaxis, raising concern over its effectiveness. Although there have been previous reports of VTE occurring in 699
6 Nguyen et al Inflamm Bowel Dis Volume 23, Number 5, May 2017 hospitalized patients with IBD despite pharmacological prophylaxis, these have been in surgical patients, whereas most in our study who developed VTE on unfractionated or low molecular weight heparin were nonsurgical. While it is possible that these patients developed subclinical deep venous thrombosis before admission, a pilot study showed that the prevalence of asymptomatic deep venous thrombosis on admission to hospital is low. 20 However, just over a third of those who developed VTE who were administered prophylaxis received it within 24 hours of admission. In our study, those who received prophylaxis within 24 hours were half as likely to develop VTE as those who never received prophylaxis, although the event numbers were too small to achieve statistical significance. Our exploratory data, however, raises the potential importance of early timing of VTE prophylaxis, which needs to be confirmed in prospective studies. It was encouraging that gastrointestinal bleeding on admission was not a deterrent against early VTE prophylaxis. Interestingly, hemodynamically nonsignificant bleeding on admission was associated with higher implementation of early VTE prophylaxis, possibly because it is often accompanied by greater disease severity and perceived increase risk of VTE. Reassuringly, our study demonstrated that VTE prophylaxis did not increase the risk of major bleeding with or without transfusion. Testing for C. difficile also varied significantly across hospital sites and specialty. Surgeons, who achieved very high rates of VTE prophylaxis, ordered C. difficile testing only half as often as by gastroenterologists and general internists. Because C. difficile is usually medically treated, the deficit in testing may reflect relative lack of awareness among surgeons. The high prevalence of C. difficile positivity in our study population is concerning considering the rising trends in North America and the association of infection with higher mortality. 6 C. difficile testing is a cardinal step in the management of hospitalized UC because the early administration of antibiotics can contribute to response to medical therapy. 7 Although clinical guidelines recommend considering rescue medical therapy if there is inadequate response within 72 hours of steroid initiation, there is sparse published data documenting the promptness of administration of medical rescue therapy. 7 Because patients who have contraindications to or fail rescue therapy (e.g., infliximab or cyclosporine) will likely require colectomy, delays in initiative rescue therapy will prolong the inhospital time to surgery, which is associated with worse outcomes. 21 Prompt administration of medical rescue therapy is a complex process of care that involves multiple stages including prebiological work-up (e.g., tuberculosis testing), access to biological therapy, and patient consent. Thus, when measuring this indicator of care, there should be some consideration for leeway and defining timely administration as being within 7 days has been suggested. 11 Using a more stringent 4-days cutoff to define prompt treatment may be less feasible and unrealistic, as indicated by our data showing only 14% of admissions meeting this standard. Our study also showed geographic variation in bowel surgery during hospitalizations for an IBD flare, with the highest rates observed in Montreal. Regional variations in IBD-related surgery have been previously reported in the United States. 12,22 However, those studies were population-based studies that included both academic centers and community centers, large and small. Variations may have been multifactorial with contributions from relative access to medical and surgical interventions, patient and physician preferences, and case-mix. It was interesting to note that such variation exists even among large tertiary and quaternary IBD centers and may be a reflection of the same factors. One possible explanation is that there may be variations in clinical threshold for admission to hospital. For example, if Montreal had a higher threshold for hospitalization, then patients who are admitted may have relatively higher disease severity than other sites and may be at greater risk for surgery. An alternative hypothesis is that sites with higher surgery rates may have had a higher proportion or individuals who had previous exposure to one or more biologics. These individuals if unresponsive to steroids would be less likely to respond to second-line medical therapy and more likely to require surgery. Prospective studies are warranted to these hypotheses and further delineate the contributing factors to the variations in surgery rate. Among the limitations of our study was that it included only IBD referral centers from Canada s largest urban centers, limiting the generalizability of the findings. Because these centers have extensive experience treating high volumes of patients with IBD, the findings with respect to quality indicators may overestimate true rates at a population-based level. Another inherent limitation of retrospective studies is potential variation in documentation of indicators in the medical chart. For example, lack of steroid responsiveness data from 1 of the 4 sites limited our analysis for variations in timely administration of second-line therapy. Despite these limitations, we conducted a large multicenter study in major Canadian cities showing substantial geographic variations in quality indicators of care and outcomes. Although adherence to quality indicators were high overall, the hospitalbased variations may present an opportunity to improve quality of care through shared clinical care pathways that standardize processes of care. The nearly ubiquitous use of electronic order entry systems in hospitals may provide an opportunity to electronically integrate these pathways. The challenge remains developing a platform that is universally compatible with the diverse range of order entry systems used by hospitals throughout the country. The significant variations in quality of care among admitting services also highlights the role of education and awareness. One intriguing opportunity is empowering the patient through education to be a partner in assuring they receive high quality of care. Patients hospitalized for IBD represent a subgroup that has poor disease prognosis. Improving inpatient quality of care provides an important opportunity to optimize their health outcomes. REFERENCES 1. Longobardi T, Bernstein CN. Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:
7 Inflamm Bowel Dis Volume 23, Number 5, May 2017 Inpatient IBD Quality of Care 2. Nguyen GC, Tuskey A, Dassopoulos T, et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and Inflamm Bowel Dis. 2007;13: Longobardi T, Bernstein CN. Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol. 2007;102: Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103: Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57: Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103: Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107: Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014; 146: Adult Inflammatory Bowel Disease Physician Performance Measures Set. Bethesda, MD: American Gastroenterological Association; 2011: Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a metaregression. Clin Gastroenterol Hepatol. 2007;5: Nguyen GC, Devlin SM, Afif W, et al. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28: Nguyen GC, Laveist TA, Gearhart S, et al. Racial and geographic variations in colectomy rates among hospitalized ulcerative colitis patients. Clin Gastroenterol Hepatol. 2006;4: Statistics Canada: population and dwelling counts, for census metropolitan areas and census agglomerations, 2011 and 2006 censuses. Available at: Accessed October 28, Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37: Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375: Kaplan GG, Lim A, Seow CH, et al. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol. 2015;21: Tinsley A, Naymagon S, Enomoto LM, et al. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis. 2013;7:e635 e Mathers B, Williams E, Bedi G, et al. An electronic alert system is associated with a significant increase in pharmacologic venous thromboembolism prophylaxis rates among hospitalized inflammatory bowel disease patients. J Healthc Qual. [published online ahead of print May 5, 2016]. doi: /JHQ Ra G, Thanabalan R, Ratneswaran S, et al. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohns Colitis. 2013;7:e479 e Nguyen GC, Wu H, Gulamhusein A, et al. The utility of screening for asymptomatic lower extremity deep venous thrombosis during inflammatory bowel disease flares: a pilot study. Inflamm Bowel Dis. 2013;19: Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134: Nguyen GC, Bayless TM, Powe NR, et al. Race and health insurance are predictors of hospitalized Crohn s disease patients undergoing bowel resection. Inflamm Bowel Dis. 2007;13:
Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients
Journal of Crohn's and Colitis (2013) 7, e479 e485 Available online at www.sciencedirect.com ScienceDirect Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel
More informationTREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
More information13-year mortality trends among hospitalized patients with inflammatory bowel disease
Sewell and Yee BMC Gastroenterology 212, 12:79 RESEARCH ARTICLE Open Access 13-year mortality trends among hospitalized patients with inflammatory bowel disease Justin L Sewell * and Hal F Yee Jr Abstract
More informationWhich is the Safest Strategy to Treat Moderate to Severe IBD?
Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor
More informationTREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationSystematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis
Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis The Harvard community has made this article openly available. Please share
More informationPREVENTING COLLATERAL DAMAGE IN THE INFLAMMATORY BOWEL DISEASE PATIENT: USING DISEASE ASSESSMENT AND PROGNOSTIC FACTORS TO OPTIMISE CLINICAL OUTCOMES
PREVENTING COLLATERAL DAMAGE IN THE INFLAMMATORY BOWEL DISEASE PATIENT: USING DISEASE ASSESSMENT AND PROGNOSTIC FACTORS TO OPTIMISE CLINICAL OUTCOMES This symposium took place on the 17 th October 2016,
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationResponse to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients
Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients Tamás Molnár 1, Klaudia Farkas 1, Tibor Nyári 2, Zoltán Szepes 1, Ferenc Nagy 1,
More informationThe exact definition of what constitutes quality of
Clinical Gastroenterology and Hepatology 2016;14:421 428 Poor Documentation of Inflammatory Bowel Disease Quality Measures in Academic, Community, and Private Practice Joseph D. Feuerstein,* Natalia E.
More informationGil Kaplan, MD, MPH, FRCPC. Eric Benchimol, MD, PhD, FRCPC
Gil Kaplan, MD, MPH, FRCPC Co-Chair, 2018 CCC Impact of IBD Report CIHR Embedded Clinician Research Chair University of Calgary Eric Benchimol, MD, PhD, FRCPC Co-Chair, 2018 CCC Impact of IBD Report Associate
More informationDeterminants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis
Research Article imedpub Journals http://www.imedpub.com/ Abstract Determinants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis Aims: The aim of our study was to identify the determinants
More informationEPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS
EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS ERIC BENCHIMOL, MD, PhD, FRCPC Associate Professor of Pediatrics and Epidemiology, University of Ottawa Pediatric Gastroenterologist, CHEO
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationCanadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn s disease
CLINICAL PRACTICE GUIDELINES Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn s disease PARTICIPANTS* Dr Remo Panaccione (Co-chair) University of Calgary
More informationPredictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease
Predictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease Jason Etzel Resident Research Forum Seattle VAMC 6/13/08 Background Increased
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationAccepted Manuscript. Improving Outcomes in Patients with Inflammatory Bowel Disease through Integrated Multi-Disciplinary Care the Future of IBD Care
Accepted Manuscript Improving Outcomes in Patients with Inflammatory Bowel Disease through Integrated Multi-Disciplinary Care the Future of IBD Care Kaci Christian, MD, Raymond K. Cross, MD, MS PII: S1542-3565(18)30746-8
More informationSafety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease
Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Vinna An, Ashwinna Asairinachan, Michael Johnston, James Keck, Paul Salama, Steven Brown, Rodney Woods Department of Colorectal
More informationPregnancy in IBD CDDW 2014
Pregnancy in IBD CDDW 2014 Brian Bressler MD, MS, FRCPC Director, Advanced IBD Training Program Clinical Assistant Professor of Medicine Division of Gastroenterology University of British Columbia Bressler
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationBridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists
ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 1-5 Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists Mohammad
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationProtocol for the management of acute severe ulcerative colitis in children
Protocol for the management of acute severe ulcerative colitis in children Introduction: Paediatric UC is severe and more extensive than adult onset UC with 6-8% presenting as pancolitis (1,2) Within five
More informationCigdem Benlice, Ipek Sapci, T. Bora Cengiz, Luca Stocchi, Michael Valente, Tracy Hull, Scott R. Steele, Emre Gorgun 07/23/2018
Does preoperative oral antibiotic or mechanical bowel preparation increase Clostridium difficile colitis after colon surgery? An assessment from ACS-NSQIP procedure-targeted database Cigdem Benlice, Ipek
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/22997 holds various files of this Leiden University dissertation Author: Wilden, Gwendolyn M. van der Title: The value of surgical treatment in abdominal
More informationAshish Malhotra 1,2,3*, K.C. Mandip 3, Aasma Shaukat 1,2,3 and Thomas Rector 2,3
Malhotra et al. Military Medical Research (2016) 3:28 DOI 10.1186/s40779-016-0098-x RESEARCH Open Access All-cause hospitalizations for inflammatory bowel diseases: Can the reason for admission provide
More informationAccepted Manuscript. Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess
Accepted Manuscript Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess PII: S1542-3565(19)30153-3 DOI: https://doi.org/10.1016/j.cgh.2019.02.013 Reference:
More informationActivity and Endoscopic measures : Crohn s disease. Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York
Activity and Endoscopic measures : Crohn s disease Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York J-F Colombel has served as consultant or advisory board member
More informationBudesonide Use and Hospitalization Rate in Crohn s Disease: Results From a Cohort at a Tertiary Care IBD Referral Center
Elmer ress Original Article J Clin Med Res. 2016;8(10):705-709 Budesonide Use and Hospitalization Rate in Crohn s Disease: Results From a Cohort at a Tertiary Care IBD Referral Center Jordan Orr a, d,
More informationTrust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)
Trust Guideline for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis (*ie aged 16 years and over) abc A guideline recommended for use In: Gastroenterology/Medical
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationFactors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer
Curr Oncol, Vol. 21, pp. 181-186 doi: http://dx.doi.org/10.3747/co.21.1963 DELAYED TIME TO ADJUVANT CHEMOTHERAPY ORIGINAL ARTICLE Factors associated with delayed time to adjuvant chemotherapy in stage
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationDiagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease
Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease Lena B. Palmer MD, Carol Q. Porter, Michael D. Kappelman MD MPH No relevant financial disclosures
More informationThe effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University
The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University Disclosures I have no conflict of interest disclosures
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationThe management of venous thromboembolism has improved. Article
Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism A Randomized, Double-Blind, Controlled Trial
More informationABSTRACT. KEY WORDS antibiotics; prophylaxis; hysterectomy
Infectious Diseases in Obstetrics and Gynecology 8:230-234 (2000) (C) 2000 Wiley-Liss, Inc. Wound Infection in Gynecologic Surgery Aparna A. Kamat,* Leo Brancazio, and Mark Gibson Department of Obstetrics
More informationOutcomes of Patients with Preoperative Weight Loss following Colorectal Surgery
Outcomes of Patients with Preoperative Weight Loss following Colorectal Surgery Zhobin Moghadamyeghaneh MD 1, Michael J. Stamos MD 1 1 Department of Surgery, University of California, Irvine Nothing to
More informationThromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort
Scandinavian Journal of Gastroenterology. 2014; 49: 820 825 ORIGINAL ARTICLE Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort RUNE ISENE
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationSignificant racial, ethnic, and socioeconomic disparities in
ORIGINAL ARTICLE Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn s Disease: Results from the ImproveCareNow Network Jennifer L. Dotson, MD, MPH,*, Michele
More informationIleal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children
Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Stephanie Jones, D.O. Surgical Fellow March 21, 2011 Ulcerative Colitis Spectrum of inflammatory bowel
More informationKey uncertainties around the evidence or technology are that the test has only been validated in biochemical studies.
pat hways PredictSure-IBD for inflammatory bowel disease prognosis Medtech innovation briefing Published: 25 March 2019 nice.org.uk/guidance/mib178 Summary The technology described in this briefing is
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationMY IBD PASSPORT. Helping to keep me on track
MY IBD PASSPORT Helping to keep me on track This health passport belongs to: Name: Address: Home phone: Other phone: Emergency contact: Phone: Other phone: In this health passport, you will be able to
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationComparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project
Comparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project Dr. Jonathan Laxton, FRCPC, R5 GIM University of Manitoba
More informationClinical Predictors of Colectomy in Patients with Ulcerative Colitis: Systematic Review and Meta-analysis of Cohort Studies
Journal of Crohn's and Colitis, 2015, 156 163 doi:10.1093/ecco-jcc/jju016 Advance Access publication December 10, 2014 Original Article Original Article Clinical Predictors of Colectomy in Patients with
More informationMalnutrition Universal Screening Tool (MUST) predicts disease activity in patients with Crohn s disease.
Canadian Journal of Nutrition ORIGINAL RESEARCH COMMUNICATION 2016: Vol 1; pp 1-5 https://doi.org.10.22433/2016/09/1 Malnutrition Universal Screening Tool (MUST) predicts disease activity in patients with
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationSociety of Trauma Nurses TraumaCon 03/22/2018
Prophylaxis Against Venous Thromboemblism (VTE) in Pediatric Trauma Society of Trauma Nurses TraumaCon 03/22/2018 Arash Mahajerin, MD, MSCr Hematology, CHOC Children s Specialists Orange, CA Disclosure
More informationTransfusion strategies in patients with cirrhosis: less is more. 1. Department of Gastroenterology, Hillingdon Hospital, London, UK
Transfusion strategies in patients with cirrhosis: less is more Evangelia M. Fatourou 1, Emmanuel A. Tsochatzis 2 1. Department of Gastroenterology, Hillingdon Hospital, London, UK 2. UCL Institute for
More informationGeographic Location, Field of Post-M.D. Training
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Other Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology Critical Care (Anes.) Public Health and
More information2017 Canadian Association of Gastroenterology Educational Needs Assessment Report
2017 Canadian Association of Gastroenterology Educational Needs Assessment Report Kevin A. Waschke MD., CM., FRCPC, FASGE VP Education Affairs, Canadian Association of Gastroenterology Karen Sparkes BASc
More informationa newsletter detailing appropriate indications of IV PPI was sent to physicians;
Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Kaplan G G, Bates D, McDonald D, Panaccione R, Romagnuolo J Record Status This is a critical abstract of an
More informationHow to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?
How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases? Alessandro Armuzzi Lead IBD Unit Complesso Integrato Columbus Fondazione Policlinico Gemelli Università
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationInflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital
Inflammatory Bowel Disease: Clinical updates Dr Jeff Chao Princess Alexandra Hospital Inflammatory bowel disease 2017 Clinical updates and future directions Pathogenesis Treatment targets Therapeutic agents
More informationDoes Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
ISPUB.COM The Internet Journal of Infectious Diseases Volume 15 Number 1 Does Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
More informationTABLE D-1 POST-M.D. TRAINEES EXITING QUEBEC TRAINING PROGRAMS IN JULY, 2014 AT THE COMPLETION OF POST-M.D. TRAINING
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology Critical Care (Anes.) Public Health and Preventive
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationΑναφορές εκβάσεων από τους ασθενείς (Patient Reported Outcomes): Μπορούν να αναβαθμίσουν τον τρόπο παρακολούθησης της νόσου; Γιώργος Μπάμιας
Αναφορές εκβάσεων από τους ασθενείς (Patient Reported Outcomes): Μπορούν να αναβαθμίσουν τον τρόπο παρακολούθησης της νόσου; Γιώργος Μπάμιας Σύγκρουση συμφερόντων Γιώργος Μπάμιας τιμητικές αμοιβές απο
More informationGeographic Location, Field of Post-M.D. Training
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology Critical Care (Anes.) Public Health and Preventive
More informationDr Adele Melton Gastroenterologist MBChB (Otago), FRACP
Dr Adele Melton Gastroenterologist MBChB (Otago), FRACP (1) Case presentation CMV in IBD (2) Prevalence (3) Treatment (4) Recommendations / Guidelines (5) Questions 60 year old male Background: UC, pancolitis
More informationDr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton
Dr. Steve Ligertwood Hospitalist Royal Columbian Hospital Regional Department Head-Hospitalist for Fraser Health Authority Project Lead BC Hospitalist VTE Collaborative Clinical Instructor, UBC School
More informationEast west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort
East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort diseasespictures.com Balazs Radnai and Martin Eigler Statistik II. Course 27.01.2014. Introduction
More informationThe 2012 SAGE Wait Time Program: Survey of Access to GastroEnterology in Canada Can J Gastroenterol 2013;27:83-9.
The 2012 SAGE Wait Time Program: Survey of Access to GastroEnterology in Canada Can J Gastroenterol 2013;27:83-9. Desmond Leddin MB, David Armstrong MD, Mark Borgaonkar MD, Ronald J Bridges MD, Carlo A
More informationORIGINAL ARTICLE. Surgery for Ulcerative Colitis in Elderly Persons. Changes in Indications for Surgery and Outcome Over Time
ORIGINAL ARTICLE Surgery for Ulcerative Colitis in Elderly Persons Changes in Indications for Surgery and Outcome Over Time Gidon Almogy, MD; David B. Sachar, MD; Carol A. Bodian, DrPH; Adrian J. Greenstein,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationA bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?
Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians
More informationThirty-Day Outcomes of Laparoscopic vs. Open Total Proctocolectomy with Ileoanal Anastomosis in Children
Thirty-Day Outcomes of Laparoscopic vs. Open Total Proctocolectomy with Ileoanal Anastomosis in Children Jeremy D. Kauffman MD, Paul D. Danielson MD, Nicole M. Chandler MD Johns Hopkins All Children s
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationCASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD
CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD Disclosure Statement NKC: No relevant conflicts to disclose. DTR: No relevant
More informationDifferentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics
38 Original Article Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics Anuchapreeda S Leelakusolvong S Charatcharoenwitthaya
More informationResearch Article The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease
Canadian Gastroenterology and Hepatology Volume 2016, Article ID 2483261, 6 pages http://dx.doi.org/10.1155/2016/2483261 Research Article The Utility of Fecal Calprotectin in the Real-World Clinical Care
More informationClostridium difficile associated diarrhea (CDAD) has emerged. Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:339 344 Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease JOSEPH F. RODEMANN,* ERIK R. DUBBERKE, KIMBERLY A. RESKE, DA HEA SEO,*
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationInflammatory Bowel Disease Causespecific Mortality: A Primer for Clinicians
Inflammatory Bowel Disease Causespecific Mortality: A Primer for Clinicians The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationI nuovi farmaci biologici: anche nell'anziano?
LE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI NELL ANZIANO I nuovi farmaci biologici: anche nell'anziano? ANNA KOHN (Roma) increasing incidence Jeuring SFG, Inflamm Bowel Dis 2016 IBD Prevalence on December
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationOxford Inflammatory Bowel Disease MasterClass. What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France
Oxford Inflammatory Bowel Disease MasterClass What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France Disclosures Consulting and/or lecture fees from Merck, Abbott,
More informationIn 2005, US health care spending increased by 6.9% to
GASTROENTEROLOGY 2008;135:1907 1913 Direct Health Care Costs of Crohn s Disease and Ulcerative Colitis in US Children and Adults MICHAEL D. KAPPELMAN,* SHERYL L. RIFAS SHIMAN, CAROL Q. PORTER, DANIEL A.
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More information